** Gilead Sciences GILD.O shares edging up 0.1% on Thurs ahead of qtrly results after the bell, with investors focused on HIV drug sales
** Analysts expect qtrly rev up ~1.9% to $6.81 bln, adjusted EPS seen at $1.79 vs loss of $1.32 yr-ago, per LSEG
** GILD stock has gained about 15% YTD, outperforming Nasdaq .IXIC, which fell ~12%
** Stock recently traded at ~13 times expected earnings, above its avg forward PE of 11
** In past 30 days, one out of 29 analysts raised EPS estimates for qtr, while one revised downwards
(Reporting by Noel Randewich)
((noel.randewich@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.